|Articles|May 1, 2016
May 2016: The Future of Hub Services: Higher Touch, Less Complexity
Author(s)Triplefin
As competition in a diversifying specialty drug business rises to fiver pitch, manufacturers are seeking new ways to differentiate the product servicing model to help their brands stand out. Triplefin's Hub-Lite™ program is adapting to these new expectations with a customized set of services geared to specialty's biggest growth segment: mid-range therapies with higher price tags than traditional retail pharmacy but significantly lower than high-end specialty pharma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results
2
Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg
3
Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson
4
Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg
5
